The concept of ?tailor-made?, protein-based, outer membrane vesicle vaccines against meningococcal disease

Holst, Johan; Feiring, Berit; Næss, Lisbeth Meyer; Norheim, Gunnstein; Kristiansen, Paul A.; Høiby, E. Arne; Bryn, Klaus; Oster, Philipp; Costantino, Paolo; Taha, Muhamed‐Kheir; Alonso, Jean-Michel; Caugant, Dominique A.; Wedege, Elisabeth; Aaberge, Ingeborg S.; Rappuoli, Rino; Rosenqvist, Einar

doi:10.1016/j.vaccine.2005.01.058

Cited by 97 publications

(61 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32,33 Thus use of such meningococcal vaccines may be limited to interventions in outbreaks of disease caused by single clones of the organism such as that in Cuba in the 1980s 6 and the current outbreak in New Zealand, 34 which has lead to the concept of tailor-made OMV vaccines for the effective control of invasive meningococcal disease. 35 The mechanisms of immunity that confer cross-reactive protection in meningococcal disease are unclear; however, it is accepted that a key aim of immunization is to elicit a functional immune response, through bactericidal and/or opsonising antibody, capable of killing meningococcal strains from the range of serogroups, serotypes and serosubtypes that cause disease. Animal models have long been used Animal models have long been used for preclinical assessment of efficacy and safety for vaccine candidates designed for human use.…”

Section: © 2 0 0 8 L a N D E S B I O S C I E N C E D O N O T D I S mentioning

confidence: 99%

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based onNeisseria lactamicaouter membrane vesicles

Finney¹,

Vaughan²,

Taylor³

et al. 2008

Human Vaccines

View full text Add to dashboard Cite

Section: © 2 0 0 8 L a N D E S B I O S C I E N C E D O N O T D I S mentioning

confidence: 99%

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based onNeisseria lactamicaouter membrane vesicles

Finney¹,

Vaughan²,

Taylor³

et al. 2008

Human Vaccines

View full text Add to dashboard Cite

“…However, no vaccine is currently available to provide universal protection against all serogroups of N. meningitidis. Capsular polysaccharide-based vaccines have been developed to protect against the main disease-associated serogroups A, C, Y, and W135; tailormade vaccines, based on outer membrane vesicles (OMV) of serogroup B epidemic strains, have been used in Norway (17), Cuba (47), and New Zealand (21) to control epidemics.…”

mentioning

confidence: 99%

Expression of Factor H Binding Protein of Meningococcus Responds to Oxygen Limitation through a Dedicated FNR-Regulated Promoter

2010

View full text Add to dashboard Cite

Factor H binding protein (fHBP) is a surface-exposed lipoprotein in Neisseria meningitidis, which is a component of several investigational vaccines against serogroup B meningococcus (MenB) currently in development. fHBP enables the bacterium to evade complement-mediated killing by binding factor H, a key downregulator of the complement alternative pathway, and, in addition, fHBP is important for meningococcal survival in the presence of the antimicrobial peptide LL-37. In this study, we investigate the molecular mechanisms involved in transcription and regulation of the fHBP-encoding gene, fhbp. We show that the fHBP protein is expressed from two independent transcripts: one bicistronic transcript that includes the upstream gene and a second shorter monocistronic transcript from its own dedicated promoter, P fhbp . Transcription from the promoter P fhbp responds to oxygen limitation in an FNR-dependent manner, and, accordingly, the FNR protein binds to a P fhbp probe in vitro. Furthermore, expression in meningococci of a constitutively active FNR mutant results in the overexpression of the fHBP protein. Finally, the analysis of fHBP regulation was extended to a panel of strains expressing different fHBP allelic variants at different levels, and we demonstrate that FNR is involved in the regulation of this antigen in all but one of the strains tested. Our data suggest that oxygen limitation may play an important role in inducing the expression of fHBP from a dedicated FNR-regulated promoter. This implies a role for this protein in microenvironments lacking oxygen, for instance in the submucosa or intracellularly, in addition to its demonstrated role in serum resistance in the blood.

show abstract

“…12 The reason for this restricted use of these vaccines is that in children, the age group with the highest risk for meningococcal disease, the immune response measured as SBA appeared rather strain-specific.…”

Section: Omv-based Vaccinesmentioning

confidence: 99%

Meningococcal B vaccine development and evaluation of efficacy

Alphen¹,

Dobbelsteen²

2008

Human Vaccines

View full text Add to dashboard Cite

The concept of ?tailor-made?, protein-based, outer membrane vesicle vaccines against meningococcal disease

Cited by 97 publications

References 12 publications

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based onNeisseria lactamicaouter membrane vesicles

Characterization of the key antigenic components and pre-clinical immune responses to a meningococcal disease vaccine based onNeisseria lactamicaouter membrane vesicles

Expression of Factor H Binding Protein of Meningococcus Responds to Oxygen Limitation through a Dedicated FNR-Regulated Promoter

Meningococcal B vaccine development and evaluation of efficacy

Contact Info

Product

Resources

About